Cargando…
THU067 Long-term Depot Specific Changes In Adipose Tissue After Treatment Of Acromegaly
Disclosure: C.M. Falch: Speaker; Self; Pfizer, Inc. K. Godang: None. T. Lekva: None. A. Heck: Speaker; Self; Ipsen, Recordati. J. Bollerslev: Advisory Board Member; Self; Pfizer, Inc. Speaker; Self; Ipsen, Pfizer, Inc. N.C. Olarescu: Speaker; Self; Pfizer, Inc., CORE2ED. Objective: Patients with act...
Autores principales: | Falch, Camilla Maria, Godang, Kristin, Lekva, Tove, Heck, Ansgar, Bollerslev, Jens, Olarescu, Nicoleta Cristina |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Oxford University Press
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10553874/ http://dx.doi.org/10.1210/jendso/bvad114.1147 |
Ejemplares similares
-
THU025 Acromegaly And Central Hyperthyroidism
por: Akhtar, Ahmad, et al.
Publicado: (2023) -
Hip Structure Analyses in Acromegaly: Decrease of Cortical Bone Thickness After Treatment: A Longitudinal Cohort Study
por: Godang, Kristin, et al.
Publicado: (2019) -
THU070 Randomized, Placebo-controlled Phase 3 Trial Protocol Assessing The Efficacy And Safety Of Octreotide Subcutaneous Depot (CAM2029) In Patients With Acromegaly
por: Ferone, Diego, et al.
Publicado: (2023) -
THU022 A Case Of Delayed Diagnosis Of Acromegaly
por: Blanchard, Kayla, et al.
Publicado: (2023) -
Trends in incidence and mortality risk for acromegaly in Norway: a cohort study
por: Falch, Camilla M., et al.
Publicado: (2022)